Male urinary dysfunction has long been viewed primarily through the lens of prostate enlargement, but this perspective may be unnecessarily limiting treatment options for millions of men experiencing bladder problems from other causes. A systematic analysis of clinical evidence suggests that phosphodiesterase-5 inhibitors, particularly tadalafil, may offer therapeutic benefits for urinary symptoms stemming from non-prostate conditions including radiation therapy complications, overactive bladder, and urinary catheter placement. The research examined five clinical trials encompassing diverse underlying conditions where traditional prostate-focused treatments would be inappropriate. Tadalafil demonstrated the most consistent improvements across multiple outcome measures, including standardized symptom scores, pain reduction, and both urinary storage and voiding functions. Sildenafil and combination approaches with alpha-blockers or anticholinergics also showed promise, though with more variable results. These findings represent a potentially significant expansion of treatment paradigms for male lower urinary tract dysfunction. Currently, men with bladder symptoms unrelated to prostate enlargement often face limited therapeutic options, frequently cycling through anticholinergic medications with modest efficacy and concerning side effects. The mechanism underlying PDE5 inhibitor benefits likely involves smooth muscle relaxation throughout the urinary tract and improved blood flow to bladder tissues. However, this analysis highlights critical knowledge gaps requiring larger, longer-term studies. The reviewed trials were relatively small and heterogeneous, making definitive clinical recommendations premature. The broader implications suggest urological practice may benefit from moving beyond prostate-centric thinking toward more comprehensive approaches recognizing the diverse pathophysiology underlying male urinary symptoms.